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Introduction
Treatment regimens comprising premixed insulin are
an established treatment option when starting insulin
in type 2 diabetes patients (1). Indeed, insulin ther-
apy is recommended by authorities such as the Inter-
national Diabetes Federation (2) and American
Association of Clinical Endocrinologists (3) in treat-
ment initiation regimens, especially where HbA1c lev-
els are high (> 10%).
Human premixed insulin, often known as biphasic
human insulin 30 (BHI 30), contains a ﬁxed soluble
human insulin component (making up 30% of the
formulation) and neutral protamine Hagedorn
(NPH) insulin (the remaining 70%). The soluble
component, when injected 30 min before a meal,
aims to lower postprandial glucose excursions, while
NPH provides basal insulin coverage. Together, they
can lower glycaemia and provide good glycaemic
control in patients with type 2 diabetes (4,5). Human
premixed insulin is, however, associated with rela-
tively high risks of hypoglycaemia, probably owing to
the mismatch between its pharmacokinetic proﬁle
and the physiological need (6).
Premixed insulin analogues, such as biphasic insu-
lin aspart 30⁄70 (BIAsp 30) and lispro mix 25 (Mix
25) are, on the other hand, associated with a phar-
macokinetic proﬁle that more closely mimics insulin
needs (7,8). As a result, better postprandial glucose
control has been seen compared with human insulin
premixes (5,8). Indeed, when used in an insulin initi-
ation regimen in a 3-month, single-centre compara-
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SUMMARY
Aims: IMPROVE
TM is an open-label, multinational, non-randomised, 26-week
observational study designed to evaluate the safety and effectiveness of biphasic
insulin aspart 30 (BIAsp 30) in routine clinical practice. Here, we report data for
patients switching to BIAsp 30 from human premixed insulin. Methods: Patients
(n = 3856) with type 2 diabetes previously receiving human premixed insulin with
or without oral antidiabetic drugs were eligible for inclusion. Demographic data,
efﬁcacy end-points (HbA1c, fasting blood glucose and postprandial blood glucose)
and safety end-points (serious adverse drug reactions, hypoglycaemia and adverse
events) were collected at baseline and ﬁnal visit. A subgroup analysis of mean
dose change was also undertaken. Results: Switching patients to BIAsp 30
resulted in signiﬁcant improvements in glycaemic control combined with a reduced
risk of hypoglycaemia. Patients who reached the HbA1c target (< 7%) had shorter
diabetes duration, lower HbA1c at baseline and needed less insulin. Over 30% of
patients were able to reach this target without experiencing hypoglycaemia over
the 26-week period. Compared with asymmetric dose switching, unit-for-unit
switching resulted in the highest proportion of patients reaching HbA1c target and
incurred the least amount of dose titration. Conclusions: A unit-for-unit switch is
the most effective as well as the simplest approach when transferring patients
from biphasic human insulin 30 to BIAsp 30.
What’s known
• Premixed insulins provide a viable option for the
treatment of type 2 diabetes.
• Premixed insulin analogues are able to mimic
more closely the physiological insulin needs than
human premixes.
What’s new
• IMPROVE
TM is a multinational, open-label,
observational study of biphasic insulin aspart 30
(BIAsp 30) treatment in type 2 diabetes in
routine clinical practice.
• Guidelines for switching patients from human
insulin premix to BIAsp 30 may be useful to
physicians wishing to beneﬁt from the
advantages of a premixed analogue regimen.
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cantly better HbA1c levels than human premix at the
end of the study (9).
Data from randomised controlled trials involving
premixed insulin analogues have consistently shown
that these insulins can signiﬁcantly lower HbA1c lev-
els and that they are an effective treatment for
patients with type 2 diabetes (8,10–13). In addition,
a large observational study (PRESENT) – using
BIAsp 30 in routine clinical practice – suggested that
patients who transferred from human premix to
BIAsp 30 for 6 months, with little increase in dose,
signiﬁcantly improved their glycaemic control and
the rate of hypoglycaemia also decreased over time
(14). In summary, there is an increasing body of evi-
dence to support the use of premix insulin analogues
over human premix insulin, but there is little evi-
dence and practical guidance on how this transfer
should be made. Indeed, it is likely that patients
receiving human premix are using it with a combina-
tion of different oral antidiabetic drugs (OADs) and
that the range of doses varies between patients.
The IMPROVE
TM study is also an international,
non-interventional, observational study carried out
to investigate the safety proﬁle and effectiveness of
BIAsp 30 in the treatment of type 2 diabetes. In this
subanalysis of the total cohort, data are reported for
patients previously using BHI 30 who switched to
BIAsp 30 at the same or lower dose and those who
upgraded to a higher dose.
Methods and patients
The study was performed in accordance with the
Declaration of Helsinki and approval was gained
from local ethics committees. All participants gave
written informed consent.
Details of the study design of IMPROVE
TM have
been published elsewhere (15). In brief, IMPROVE
TM
was a 26-week, open-label, non-randomised, multi-
centre observational study in 11 countries (Canada,
China, Greece, Gulf region, India, Iran, Italy, Japan,
Poland, Russia and South Korea). Participating phy-
sicians received remuneration for the time spent reg-
istering patient data in accordance with local rules
and regulations. Patients with type 2 diabetes being
prescribed BIAsp 30 by their physician in routine
clinical practice were eligible for inclusion into the
study, but data from the subanalysis reported here
only includes those patients who were previously
receiving BHI 30 with or without (±) OADs.
BIAsp 30 (±OADs) was prescribed by the physi-
cian as part of routine treatment and administered
once, twice or three times daily, depending on the
patient’s needs; the dosage was also adjusted individ-
ually, as required, and information about the dose
was recorded at baseline, 3 months and at the ﬁnal
visit (after 6 months).
The primary end-point was the incidence of major
hypoglycaemic events reported as a serious adverse
drug reaction (SADR) during the 26-week BIAsp 30
treatment period. Secondary end-points included fur-
ther safety parameters: additional SADRs, adverse
drug reactions and number of major and minor
hypoglycaemic events (daytime and nocturnal). Major
hypoglycaemic events were deﬁned as events with
symptoms consistent with hypoglycaemia in which
the subject was unable to treat him⁄herself and that
had one of the following characteristics: (i) blood glu-
cose measurement < 2.8 mmol⁄l( <5 0m g⁄dl) or (ii)
reversal of symptoms after either glucagon or intrave-
nous glucose administration. Minor hypoglycaemic
events were deﬁned as events with either symptoms of
hypoglycaemia that resolved with oral carbohydrate
intake, glucagon or intravenous glucose or any symp-
tomatic or asymptomatic blood glucose < 2.8 mmol⁄l
(< 50 mg⁄dl). Finally, nocturnal hypoglycaemic
events were classed as symptomatic events consistent
with hypoglycaemia that occurred while sleeping,
between bedtime after the evening insulin injection
and before getting up in the morning [before morn-
ing determination of fasting blood glucose (FBG) and
morning injection]. Major hypoglycaemic events were
recorded over 13 weeks before each visit, while minor
hypoglycaemic events were recorded over 4 weeks
before each visit. These data were calculated as events
per patient year.
Any changes in weight (kg) and body mass index
(BMI, kg⁄m
2) were calculated from recorded data.
Measurements of effectiveness were recorded as addi-
tional secondary end-points, including HbA1c (%),
proportions of patients reaching targets of HbA1c
< 7.0%, FBG (mmol⁄l), postprandial blood glucose
(PPBG; mmol⁄l) after all main meals. Finally, patient
treatment satisfaction was recorded at the start and
end of treatment using the DiabMedSat question-
naire (16).
The full analysis set was deﬁned as all patients
with a baseline visit and who had been prescribed
BIAsp 30 at least once. The efﬁcacy analysis set was
deﬁned as above, but only included patients who also
had one measurement of hypoglycaemic event, blood
glucose, weight or HbA1c at baseline and ﬁnal visit.
Patient data presented in this manuscript are for
those who had values for end-points at both the
baseline and the end of study visits.
Statistical methods
Statistical comparisons of BIAsp 30 end-points at
baseline (week 0) and ﬁnal visit (approximately week
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ous variables, and with Wilcoxon signed-rank tests
for discrete variables. Inﬂuence of predictor variables
on the change in outcome variables was evaluated
with ANCOVA models for continuous outcome vari-
ables and logistic models for discrete outcome vari-
ables. All testing used two-sided tests with the
criteria set at a = 0.05.
Results
Patients
Baseline demographic data are shown in Table 1.
The majority of patients (n = 3413⁄3856, 83.3%)
injected BHI 30 twice a day prestudy, and over half
of patients in this subanalysis received at least two
OADs. In the analyses that follow, overall cohort
data have been presented, and in addition, patients
have been stratiﬁed according to dose, i.e. whether
they switched from BHI 30 to BIAsp 30 unit-for-unit
or to a lower dose (< 90% of BHI dose) or a higher
dose (> 10% dose increase).
Effectiveness
Mean overall HbA1c reduction from baseline was
1.84% at ﬁnal visit (Table 2). Switching to BIAsp 30
from a human premix insulin regimen facilitated
mean reductions in all measured indices of glycaemic
control after 6 months of treatment: HbA1c (20%
reduction), FBG (34% reduction) and PPBG (33%
reduction) were all improved (Table 2).
At baseline, 3405 patients had an HbA1c ‡ 7.0%,
and 253 patients (6.3%) had an HbA1c < 7.0% (data
were missing for 198 patients). By the end of the
study, 1489 patients (40.5%) achieved an HbA1c
< 7.0%. The demographics and outcome parameters
Table 1 Patient demographics and prestudy therapy details
Demographic
Patients previously receiving human
premix ± OADs (n = 3856)
Age (years) 57.0 ± 11.5
Gender, male⁄female (%) 2230⁄1623 (57.9⁄42.1%)
BMI (kg⁄m
2) 26.3 ± 4.9
Duration of diabetes (years) 10.7 ± 6.9
Prestudy BHI 30 dose
lU 33.4 ± 17.8
lU⁄kg 0.49 ± 0.24
Percentage of patients injecting BHI 30 once⁄twice⁄three⁄four times daily prestudy (%) 11.4⁄84.0⁄4.4⁄0.2
Percentage of patients receiving 1, 2, > 2 OADs prestudy (%)* 26⁄38⁄16
Data are mean ± SD unless stated otherwise. *OAD information missing for 20% of patients. BMI, body mass index; BHI, biphasic
human insulin 30; OAD, oral antidiabetic drug.
Table 2 Change from baseline in safety and effectiveness parameters when using biphasic insulin aspart 30 for 6 months
Effectiveness parameter Baseline
3-month
follow up
Final visit at
6 months
Change from baseline
to ﬁnal visit p-value
HbA1c, % 9.21 ± 1.71 7.85 ± 1.18 7.37 ± 1.24 )1.84 ± 1.63 < 0.0001
FBG, mmol⁄l 10.29 ± 3.05 7.71 ± 1.96 6.81 ± 1.62 )3.48 ± 2.98 < 0.0001
PPBG breakfast, mmol⁄l 14.91 ± 4.04 10.92 ± 2.75 9.42 ± 2.32 )5.48 ± 4.04 < 0.0001
PPBG lunch, mmol⁄l 14.75 ± 4.61 10.42 ± 2.73 9.57 ± 2.55 )5.17 ± 4.41 < 0.0001
PPBG dinner, mmol⁄l 11.53 ± 3.70 8.95 ± 2.01 8.29 ± 1.79 )3.24 ± 4.10 < 0.0001
Major hypoglycaemia (events⁄patient⁄year) 0.355 n⁄a 0.028 0.331 < 0.0001
Minor hypoglycaemia (events⁄patient⁄year) 7.725 1.907 2.025 5.700 < 0.0001
Nocturnal minor hypoglycaemia (events⁄patient⁄year) 2.578 0.411 0.408 2.170 < 0.0001
Treatment satisfaction, % patients very⁄extremely satisﬁed 16.10% n⁄a 56.90% n⁄a < 0.0001
Values obtained at the 3-month follow-up visit are also provided. Values are mean ± SD. Data from patients with values for each timepoint. FBG, fasting blood glu-
cose; PPBG, postprandial glucose. Main cohort (n = 3856).
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‡ 7.0% at ﬁnal visit are shown in Table 3. Patients
who reached this target had signiﬁcantly lower BMI
and duration of diabetes than those who did not
reach this target (BMI: 25.9 vs. 26.4 kg⁄m
2, respec-
tively, p = 0.0077; duration of diabetes: 9.9 vs.
11.3 years respectively, p < 0.0001; Table 3). Glycae-
mic control at baseline was also signiﬁcantly better
in patients who reached HbA1c < 7.0% compared
with those whose ﬁnal HbA1c was ‡ 7.0% (HbA1c:
8.47 vs. 9.71%, respectively, p < 0.0001; FBG: 9.84
vs. 10.59 mmol⁄l, p < 0.0001; PPBG: 14.20 vs.
15.49 mmol⁄l, p < 0.0001; Table 3).
The majority of patients who achieved an HbA1c
< 7.0% did so without hypoglycaemia (n = 1483⁄
1489) – major, minor or nocturnal when switching
Table 3 Demographics and safety and effectiveness outcomes for subjects who had HbA1c ‡ 7.0% and < 7.0% at ﬁnal
visit
Study measure (n = 3856)
HbA1c ‡ 7%
(n = 2186)
HbA1c <7 %
(n = 1489)
p-value for
between groups
Age (years) 56.9 ± 11.28 57.1 ± 11.49 0.727
Gender, male⁄female (%) 1269⁄9.7 (58.1⁄41.9) 843⁄644 (56.7⁄43.3) 0.413
BMI (kg⁄m
2) 26.4 ± 4.8 25.9 ± 4.4 0.0077
Duration of diabetes (years) 11.3 ± 6.8 9.9 ± 6.6 < 0.0001
Duration of prestudy insulin therapy (years) 2.9 ± 3.3 2.5 ± 3.3 < 0.0001
Percentage of patients injecting BHI 30 once⁄
twice⁄three⁄four times daily prestudy (%)
11.7⁄85.2⁄3.2 10.6⁄83.9⁄5.4 0.002
HbA1c,%
Baseline 9.71 ± 1.66 8.47 ± 1.50 < 0.0001
Final visit 8.02 ± 1.18 6.40 ± 0.43 < 0.0001
Change )1.69 ± 1.68*** )2.07 ± 1.52*** < 0.0001
FBG, mmol⁄l
Baseline 10.59 ± 3.11 9.84 ± 2.77 < 0.0001
Final visit 7.27 ± 1.79 6.14 ± 1.03 < 0.0001
Change )3.33 ± 3.10*** )3.70 ± 2.71*** 0.0003
PPBG breakfast, mmol⁄l
Baseline 15.49 ± 4.08 14.20 ± 3.86 < 0.0001
Final visit 10.06 ± 2.07 8.62 ± 1.81 < 0.0001
Change )5.43 ± 4.12*** )5.59 ± 3.94*** 0.367
Major hypoglycaemia (events⁄patient⁄year)
Baseline 0.362 ± 2.30 0.345 ± 1.84 0.325
Final visit 0.018 ± 0.36 0.020 ± 0.32 0.625
Minor hypoglycaemia (events⁄patient⁄year)
Baseline 6.82 ± 19.31 8.73 ± 22.94 0.0023
Final visit 1.83 ± 16.39 2.34 ± 8.89 < 0.0001
Nocturnal hypoglycaemia (minor events⁄patient⁄year)
Baseline 2.31 ± 10.31 2.78 ± 9.17 < 0.0001
Final visit 0.32 ± 3.22 0.54 ± 3.15 < 0.0001
Treatment satisfaction (% patients very⁄extremely satisﬁed)
Baseline 17.6 14.9 0.366
Final visit 52.8 61.0 0.0416
Prestudy BHI 30 dose (IU⁄kg) 0.50 ± 0.25 0.47 ± 0.23 0.0001
Mean dose of BIAsp 30 (U⁄kg ± SD)
Baseline 0.47 ± 0.22 0.44 ± 0.21 < 0.0001
Final visit 0.48 ± 0.23 0.43 ± 0.19 < 0.0001
Change 0.01 ± 0.17* )0.02 ± 0.17** 0.0002
BIAsp 30 bid (% patients)
Baseline 85.2 83.9 0.0021
Final visit 85.5 85.6 0.5050
Values are mean ± SD. *p < 0.01, **p < 0.001, ***p < 0.0001. BMI, body mass index; BHI 30, biphasic human insulin 30; FBG,
fasting blood glucose; PPBG, postprandial blood glucose; BIAsp 30, biphasic insulin aspart 30; bid, twice daily.
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was a 2.07% reduction in HbA1c, from a mean base-
line HbA1c of 8.47% to 6.40% at end-point (p <
0.0001) after 6 months of treatment with BIAsp 30.
When switching from BHI 30 to BIAsp 30, signiﬁ-
cant reductions in HbA1c, FBG and PPBG were
achieved regardless of whether the dose switch was
unit-for-unit, or to a lower or higher dose at the
time of transfer (Table 4). However, baseline values
of these parameters were higher and reductions at
ﬁnal visit greater in those switching to a higher insu-
lin dose. More patients achieved a target HbA1c
< 7.0% when switching unit-for-unit (43.7%) than
when switching to a lower (38.5%) or higher dose
(32.2%) (Table 4).
Safety
The rate of major hypoglycaemic events reported as
SADRs (events⁄patient⁄year) was lower at the end of
the study when using BIAsp 30 compared with the
baseline rate, when BHI 30 was the treatment
(p < 0.0001; Table 2, Figure 1). No other SADRs
Table 4 Change in dose from baseline to end-point for three subgroups: patients switching on a unit-for-unit basis,
those experiencing a lower dose and those experiencing a dose increase
Unit-for-unit
switchers
(n = 1399)
Patients switching
to a lower dose
(n = 1285)
Patients switching
to a higher dose
(n = 1172)
Between groups
comparison
p-value
HbA1c,%
Baseline 9.0 ± 1.6 9.2 ± 1.9 9.4 ± 1.6 < 0.0001
Final visit 7.3 ± 1.2 7.4 ± 1.3 7.4 ± 1.2 0.09
Change )1.7 ± 1.6*** )1.8 ± 1.7*** )2.0 ± 1.6*** < 0.0001
% Patients reaching HbA1c <7 % 43.70% 38.50% 32.20% 0.0011
FBG, mmol⁄l
Baseline 10.0 ± 3.0 10.2 ± 3.1 10.7 ± 3.1 < 0.0001
Final visit 6.7 ± 1.5 6.8 ± 1.6 6.9 ± 1.8 0.12
Change )3.3 ± 2.9*** )3.3 ± 2.9*** )3.9 ± 3.0*** < 0.0001
PPBG breakfast, mmol⁄l
Baseline 14.4 ± 3.9 14.6 ± 4.2 15.7 ± 3.9 < 0.0001
Final visit 9.2 ± 2.1 9.4 ± 2.3 9.7 ± 2.5 0.0005
Change )5.2 ± 3.8*** )5.2 ± 4.2*** )6.0 ± 4.1*** < 0.0001
Major hypoglycaemia (events⁄patient⁄year)
Baseline 0.44 0.25 0.36 0.0004
Final visit 0.04*** < 0.01*** 0.01*** 0.0048
Minor hypoglycaemia (events⁄patient⁄year)
Baseline 8.95 7.84 6.14 < 0.0001
Final visit 2.68*** 1.24*** 2.11*** 0.0002
Nocturnal hypoglycaemia (minor events⁄patient⁄year)
Baseline 3.31 2.45 1.84 < 0.0001
Final visit 0.44*** 0.22*** 0.58*** < 0.0001
Treatment satisfaction (% patients very⁄extremely satisﬁed)
Baseline 16.40% 15.30% 16.40% 0.93
Final visit 55.30% 57.40% 60.00% 0.60
Prestudy BHI 30 dose
(IU⁄kg) 0.49 ± 0.22 0.59 ± 0.26 0.36 ± 0.19 < 0.0001
bid (% patients) 89.30% 87.00% 74.50% < 0.0001
Mean dose of BIAsp 30 (U⁄kg ± SD)
Baseline 0.49 ± 0.22 0.39 ± 0.19 0.52 ± 0.2 < 0.0001
Final visit 0.49 ± 0.22 0.43 ± 0.21 0.48 ± 0.2 < 0.0001
Change 0.00 ± 0.17
NS 0.04 ± 0.17*** )0.03 ± 0.17*** < 0.0001
BIAsp 30 bid (% patients)
Baseline 89.30% 76.30% 87.50% < 0.0001
Final visit 88.30% 81.90% 86.20% < 0.0001
Values are mean ± SD. ***p < 0.0001 vs. baseline, ns = not signiﬁcant.; BHI 30, biphasic human insulin 30; bid, twice daily; BIAsp
30, biphasic insulin aspart 30; FBG, fasting blood glucose; PPBG, postprandial blood glucose.
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also decreased signiﬁcantly from baseline at ﬁnal visit
(both p < 0.0001; Table 2, Figure 1).
Major hypoglycaemia rates were similar in patients
who reached an HbA1c < 7.0% and in those whose
ﬁnal HbA1c was ‡ 7.0% (0.345 vs. 0.362 events⁄pati-
ent-year; Table 3), while minor and nocturnal hypo-
glycaemia rates were higher in those reaching this
target (minor: 8.73 vs. 6.82 events⁄patient-year,
p = 0.0023; nocturnal: 2.78 vs. 2.31 events⁄patient-
year, p < 0.0001; Table 3).
Major, minor and nocturnal hypoglycaemia rates
were signiﬁcantly reduced from baseline regardless of
whether the dose switch from BHI 30 to BIAsp 30
was unit-for-unit, or to a lower or higher dose at the
time of transfer (all p < 0.0001; Table 4). Patients
who switched unit-for-unit had the highest major
and minor hypoglycaemia rates at baseline and ﬁnal
visit (Table 4).
Weight change
For patients aged over 18 years (n = 3819 for those
supplying baseline and ﬁnal visit data), there was a
statistically signiﬁcant but minimal weight loss in
this subpopulation, from 69.2 ± 13.8 kg at baseline
to 69.2 ± 13.4 kg after 6 months (difference from
baseline, )0.06 ± 4.86 kg; p = 0.0226). Patients
under 18 years were not included in the analyses, as
weight gain would have been complicated by growth
rate.
Among the dosing subgroups, patients who
switched from BHI 30 to BIAsp 30 unit-for-unit
gained 0.27 ± 5.56 kg (70.78 ± 15.13 kg at baseline
to 71.04 ± 15.17 kg at ﬁnal visit, p < 0.0001), those
who switched to a lower dose had a weight reduction
of 0.31 ± 4.12 kg (67.48–67.17 kg, p = 0.0098), and
those who switched to a higher dose had no sig-
niﬁcant weight change: )0.16 ± 4.69 kg (69.31 ±
13.17 kg to 69.15 ± 12.45 kg, p = 0.2272).
BIAsp 30 dose
At baseline, patients received a mean dose of 31.9 ±
16.7 U (0.46 ± 0.22 U⁄kg) BIAsp 30. After 3 months,
the dose had slightly increased to 32.5 ± 18.4 U
(0.47 ± 0.22 U⁄kg). At the ﬁnal visit, the mean
BIAsp 30 dose was 32.3 ± 18.4 U (0.47 ± 0.22
U⁄kg), change from baseline: 0.00 ± 0.17. For
patients who achieved an HbA1c < 7.0% without
hypoglycaemia, total insulin daily dose was 29.6 ±
14.3 U (0.44 ± 0.21 U⁄kg) at baseline and 28.8 ±
14.2 U (0.43 ± 0.19 U⁄kg) at ﬁnal visit (p = 0.0003).
At the point of switching, most patients
(n = 3188, 83.4%) used BIAsp 30 twice daily. The
remaining patients used BIAsp 30 once (n = 459,
12.3%) or three times daily (n = 160, 4.3%). By the
end of the study, the proportion of patients taking
BIAsp 30 once, twice or three times daily was 9.3%
(n = 338), 84.7% (n = 3088) and 5.9% (n = 216)
respectively. Very few patients (n = 4, 0.1%) used
BIAsp 30 four times a day.
In terms of starting regimen, 36.3% of patients
switched from BHI 30 to BIAsp 30 on a unit-for-unit
basis, 33.3% started BIAsp 30 on a lower dose than
BHI 30 and 30.9% upgraded to a higher dose of
BIAsp 30 than their previous premixed human insu-
lin. Of these approaches, the unit-for-unit basis
incurred the least change in ﬁnal dose at 6 months
(+0.2 U, p = ns) and patients across each subgroup
tended to start, and stay, on a twice daily dosing reg-
imen (Table 4).
Patient satisfaction
When patients were asked to comment on how satis-
ﬁed they were with their treatment at baseline with
BHI 30 and at the end of the study (i.e. following a
switch to BIAsp 30), more patients answered ‘very
satisﬁed or extremely satisﬁed’ at the end of the
study: 16.1% (baseline), 56.9% (end of the study)
(p < 0.0001 for change from baseline).
Discussion
Findings from this observational study suggest that
patients switching from a human-based premix regi-
men to a regimen with BIAsp 30 had lower rates of
hypoglycaemia with improved glycaemic control, and
an increased treatment satisfaction score. A slight
weight loss was also observed which, while statisti-
cally signiﬁcant, was deemed clinically irrelevant, and
could be explained by the negligible change in insu-
lin dose. These data support the conclusions of a
previous observational study with BIAsp 30 (14),
which suggested an improved balance between blood
glucose control and tolerability for premixed ana-
logues, possibly due to a pharmacodynamic proﬁle
Figure 1 Rates of major (left) and minor (right)
hypoglycaemia were lower at the ﬁnal visit compared with
the baseline visit in the main cohort. ***p < 0.0001 vs.
baseline
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in healthy subjects (7,17). Independent analyses of a
cohort of patients who switched from BHI
30 + OAD to BIAsp 30 + OAD and stayed on BIAsp
30 + OAD (data not presented) yielded similar
results for the primary end-point, as well as other
study measures. This indicates that there was no con-
founding inﬂuence of patients with missing OAD
information, or of adding or adjusting OADs or dose
during the course of the study on the results.
Ordinarily, part of the value of an observational
study is its ability to verify the evidence of clinical
trials in a real world setting (18). Here, however,
these analyses represent a novel approach to explor-
ing the effects of a particular treatment regimen
switch, and as such, can provide valuable insight into
how best to manage dose when switching from BHI
30 to BIAsp 30. Patients who switched were divided
into three categories: those switching on a unit-for-
unit basis, those decreasing their dose and those
increasing their dose upon BIAsp 30 initiation. Of
these approaches, the ﬁrst group incurred the small-
est subsequent dose increase over the course of the
study, with the other two groups increasing and
decreasing dose respectively (both p < 0.05). Inter-
estingly, all three groups showed signiﬁcant improve-
ments in HbA1c, FBG and PPBG after 6 months of
BIAsp 30 therapy, although a greater proportion of
those who switched unit-for-unit achieved the HbA1c
target of < 7.0% compared with those who switched
to a lower or higher dose. Baseline glycaemic control
was also better in the unit-for-unit switchers, so the
similar end-of-study results across all groups was
achieved by titrating up the dose in those who
switched to a lower dose and by titrating down in
those who switched to a higher dose.
The ﬁnal insulin weight-adjusted dose observed
here was 0.47 U⁄kg, which is similar to that found
in the China cohort of the PRESENT observational
study, but higher than that reported in the India
cohort (19,20). While these data must be viewed
with the caveat that patients’ therapy should be con-
sidered on a case-by-case basis, these ﬁndings suggest
that switching to BIAsp 30 can be effectively done
using a simple unit-for-unit dose switch. Moreover,
injection frequency did not change signiﬁcantly from
baseline to end-point for any group, with twice-daily
dosing being the most common.
One third of patients were able to reach the Amer-
ican Diabetes Association (ADA) target HbA1c of
< 7% (21) without experiencing hypoglycaemia.
Interestingly, the mean BIAsp 30 dose decreased by
0.88 U ()0.02 U⁄kg) from baseline (p = 0.003), sug-
gesting that the signiﬁcant reduction in blood glu-
cose levels was not achieved by up-titration. This
subgroup represented the majority of patients who
achieved this HbA1c target at the ﬁnal visit, high-
lighting what a barrier hypoglycaemia can be to
achieving glycaemic control. Patients in this sub-
group had, on average, a lower HbA1c at baseline
(8.47% vs. 9.21% for the overall study population),
so better glycaemic control and lower BIAsp 30 doses
following the switch may have helped these patients
stay free from hypoglycaemia. The current recom-
mended threshold for modifying or intensifying a
failing diabetes treatment is an HbA1c ‡ 7% (22).
From the present data, switching from BHI 30 to
BIAsp 30 provides an effective option for patients.
Whilst our data support the value of optimising a
patient’s regimen before glycaemic control dimin-
ishes, it is likely that the mean baseline HbA1c of
> 9% reﬂects, a suboptimal control that is common
in many populations (23,24). It is therefore reassur-
ing to note that patients with a higher baseline
HbA1c also gained signiﬁcant beneﬁts in glycaemic
control and tolerability. This is evident from the
results of those patients who reached a target HbA1c
< 7.0% compared with those who had HbA1c levels
‡ 7.0% (Table 3). The patients who reached this tar-
get had a shorter diabetes duration, lower HbA1c and
needed less insulin, suggesting that it is easier to get
optimal glycaemic control with BIAsp 30 when pre-
scribing this insulin earlier.
These factors may have contributed to the
improved treatment satisfaction scores after switch-
ing to BIAsp 30. While an insulin-speciﬁc question-
naire such as the Insulin Treatment Satisfaction
Questionnaire (25) may have been more appropriate
for this cohort, as all patients were previously treated
with human premixed insulin, and may possibly
have resulted in greater improvements in score, it is
encouraging that substantial improvements were
achieved with the more general diabetes therapy
questionnaire, the DiabMedSat.
Weight changes, although signiﬁcant in some
groups (overall and in patients switching unit-for-
unit or to a lower dose) were small and clinically
irrelevant – all < 0.5 kg. As expected, patients switch-
ing to a lower dose ﬁnished on a lower dose than
their previous therapy (BHI 30), and so lost 0.31 kg.
What is more surprising is that patients who
switched to a higher dose and ﬁnished on a higher
dose than their previous therapy still managed to
lose a small amount of weight ()0.16 kg). This may
be the result of dietary advice received during physi-
cian visits and perhaps a reduced need to ingest
sugar due to the signiﬁcantly lower rates of major,
minor and nocturnal hypoglycaemia. These factors
may also have had an impact on the observed mini-
mal weight changes in the other subgroups.
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individual countries, the cost-effectiveness issues of
switching patients from BHI 30 to BIAsp 30 have
not been addressed in this report on a global cohort.
However, results of an analysis based on data from
the PRESENT study indicate that switching to BIAsp
30 from BHI 30 in the Chinese setting was associated
with increased direct medical costs offset by reduced
diabetes-related complication costs over patient life-
times (26).
While observational studies enable inclusion of a
more heterogeneous population due to relaxed
inclusion criteria, they have limitations which must
be taken into account when evaluating data. Lack of
randomisation combined with no comparator or
placebo control may undermine the signiﬁcance of
ﬁndings, and patient drop-out with missing data
may also compromise statistical analyses. Also, clini-
cal practice may vary considerably between coun-
tries, clinical centres and individual physicians.
Notwithstanding the caveats these factors necessitate,
our ﬁndings nevertheless show clinically relevant
beneﬁts for patients switching to BIAsp 30 from
BHI and suggest a straightforward approach to han-
dling dose.
In conclusion, this subanalysis from the IMPRO-
VE
TM study supports the positive implications from
earlier controlled and observational studies on
switching of patients from human premix to BIAsp
30 in routine care. While patients who were switched
unit-for-unit or switched to a lower or higher dose
all had signiﬁcant improvements from baseline in
glycaemic control and hypoglycaemia at ﬁnal visit,
those who were switched unit-for-unit had the best
baseline and end-of-study glycaemic control. These
ﬁndings support the recently updated European
Association for the Study of Diabetes and ADA con-
sensus guidelines for treatment management in type
2 diabetes (22), which state that earlier intervention
to improve glycaemic control enables the greatest
beneﬁts to patients.
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